{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:54:35Z","timestamp":1794592475082,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T00:00:00Z","timestamp":1654905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T00:00:00Z","timestamp":1654905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","award":["2022GOYIA-3952183205"],"award-info":[{"award-number":["2022GOYIA-3952183205"]}],"id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000042","name":"Amgen Foundation","doi-asserted-by":"publisher","award":["(GHCCOPS-DON-459160)"],"award-info":[{"award-number":["(GHCCOPS-DON-459160)"]}],"id":[{"id":"10.13039\/100000042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Implement Sci Commun"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The recent implementation of novel therapies has accelerated  progress in pediatric cancer care. Despite the significantly poorer survival of patients in low- and middle-income countries (LMICs), administation\u00a0complexities  and other significant resource barriers have limited the translation of these novel therapies in these regions. This study aims to develop a model that can be used to support the implementation of novel therapies, such as blinatumomab (bispecific antibody therapy for B-cell acute lymphoblastic leukemia [B-ALL]) in LMIC centers, with the long-term goal of developing an implementation framework for similar future efforts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, mixed methods will be applied to understand the key contextual considerations that can be accounted for through a training program and prospectively designed implementation activities. The Consolidated Framework for Implementation Research will guide the activities related to implementation evaluation in parallel with a drug donation program. A multidisciplinary research team comprising high- and low-middle income healthcare professionals, industry, and implementation scientists has been assembled with the common goal of improving safe access to blinatumomab. To assess the factors affecting blinatumomab administration, semi-structured interviews with diverse collaborators and quantitative assessments of organizational characteristics will be conducted, together with quantitative and qualitative assessments of feasibility, acceptability, appropriateness, and cost of blinatumomab implementation. A quantitative assessment of stakeholder perceptions of different implementation strategies used as part of the multifaceted approach will also be performed. Finally, we will examine the key domains and processes used and construct the implementation roadmap for translation of novel therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study will rigorously develop an implementation roadmap for translation of novel therapies in low-resource settings. The knowledge gained in the formative assessment will reveal the priority areas and key implementation strategies. Thereby, the resultant roadmap will facilitate future scale-out strategies for novel therapies in LMICs, thus increasing access, building capacity for management, and ultimately improving the care for children in LMICs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s43058-022-00310-5","type":"journal-article","created":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T04:02:56Z","timestamp":1654920176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Evaluating blinatumomab implementation in low- and middle-income countries: a study protocol"],"prefix":"10.1186","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3352-0841","authenticated-orcid":false,"given":"Caitlyn","family":"Duffy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Jeha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Pauley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"Sniderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niharendu","family":"Ghara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naureen","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Narula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nickhill","family":"Bhakta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Rodriguez-Galindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,11]]},"reference":[{"issue":"7","key":"310_CR1","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/S1470-2045(19)30273-6","volume":"20","author":"ZJ Ward","year":"2019","unstructured":"Ward ZJ, Yeh JM, Bhakta N, Frazier AL, Girardi F, Atun R. Global childhood cancer survival estimates and priority-setting: a simulation-based analysis. Lancet Oncol. 2019;20(7):972\u201383. https:\/\/doi.org\/10.1016\/S1470-2045(19)30273-6.","journal-title":"Lancet Oncol"},{"issue":"5","key":"310_CR2","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1097\/MPH.0b013e318290c3d6","volume":"35","author":"B Reism\u00fcller","year":"2013","unstructured":"Reism\u00fcller B, Peters C, Dworzak MN, P\u00f6tschger U, Urban C, Meister B, Schmitt K, Dieckmann K, Gadner H, Attarbaschi A, Mann G, Austrian ALL-BFM (Berlin-Frankfurt-M\u00fcnster) Study Group. Outcome of children and adolescents with a second or third relapse of acute lymphoblastic leukemia (ALL): a population-based analysis of the Austrian ALL-BFM (Berlin-Frankfurt-M\u00fcnster) study group. J Pediatr Hematol Oncol. 2013;35(5):e200-4. https:\/\/doi.org\/10.1097\/MPH.0b013e318290c3d6. PMID: 23652878.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"9","key":"310_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41408-018-0117-0","volume":"8","author":"L Gore","year":"2018","unstructured":"Gore L, Locatelli F, Zugmaier G, et al. Survival after blinatumomab treatment in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia. Blood Cancer J. 2018;8(9):80.","journal-title":"Blood Cancer J"},{"issue":"9","key":"310_CR4","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jama.2021.0669","volume":"325","author":"PA Brown","year":"2021","unstructured":"Brown PA, Ji L, Xu X, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325(9):833\u201342. https:\/\/doi.org\/10.1001\/jama.2021.0669.","journal-title":"JAMA"},{"issue":"9","key":"310_CR5","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2021.0987","volume":"325","author":"F Locatelli","year":"2021","unstructured":"Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, Parasole R, Linderkamp C, Flotho C, Petit A, Micalizzi C, Mergen N, Mohammad A, Kormany WN, Eckert C, M\u00f6ricke A, Sartor M, Hrusak O, Peters C, Saha V, Vinti L, von Stackelberg A. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325(9):843\u201354. https:\/\/doi.org\/10.1001\/jama.2021.0987. PMID: 33651091; PMCID: PMC7926287.","journal-title":"JAMA"},{"key":"310_CR6","volume-title":"GLOBOCAN 2018","author":"J Ferlay","year":"2018","unstructured":"Ferlay J. GLOBOCAN 2018. Lyon: World Health Organization International Agency for Research on Cancer; 2018."},{"key":"310_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ctrv.2016.06.002","volume":"48","author":"F Tartari","year":"2016","unstructured":"Tartari F, Santoni M, Burattini L, Mazzanti P, Onofri A, Berardi R. Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: recent insights and future challenges. Cancer Treat Rev. 2016;48:20\u20134. https:\/\/doi.org\/10.1016\/j.ctrv.2016.06.002. Epub 2016 Jun 7. PMID: 27310708).","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"310_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/MOP.0b013e32835c1cbe","volume":"25","author":"C Rodriguez-Galindo","year":"2013","unstructured":"Rodriguez-Galindo C, Friedrich P, Morrissey L, Frazier L. Global challenges in pediatric oncology. Curr Opin Pediatr. 2013;25(1):3\u201315. https:\/\/doi.org\/10.1097\/MOP.0b013e32835c1cbe.","journal-title":"Curr Opin Pediatr"},{"key":"310_CR9","unstructured":"Middle Income Countries Overview (worldbank.org).\u00a0https:\/\/www.worldbank.org\/en\/country\/mic\/overview."},{"issue":"10125","key":"310_CR10","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nik\u0161i\u0107 M, Bonaventure A, Valkov M, Johnson CJ, Est\u00e8ve J, Ogunbiyi OJ, Azevedo E, Silva G, Chen WQ, Eser S, Engholm G, Stiller CA, Monnereau A, Woods RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP, CONCORD Working Group. Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37\u2008513\u2008025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(17)33326-3. Epub 2018 Jan 31. PMID: 29395269; PMCID: PMC5879496.","journal-title":"Lancet"},{"issue":"4","key":"310_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.17.00126","volume":"4","author":"A Fundytus","year":"2018","unstructured":"Fundytus A, Sullivan R, Vanderpuye V, Seruga B, Lopes G, Hammad N, Sengar M, Hopman WM, Brundage MD, Booth CM. Delivery of global cancer care: an international study of medical oncology workload. J Glob Oncol. 2018;4(4):1\u201311. https:\/\/doi.org\/10.1200\/JGO.17.00126. Epub 2017 Dec 15. PMID: 29244632; PMCID: PMC6180784.","journal-title":"J Glob Oncol"},{"issue":"9747","key":"310_CR12","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/S0140-6736(10)61152-X","volume":"376","author":"P Farmer","year":"2010","unstructured":"Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, Atun R, Blayney D, Chen L, Feachem R, Gospodarowicz M, Gralow J, Gupta S, Langer A, Lob-Levyt J, Neal C, Mbewu A, Mired D, Piot P, Reddy KS, Sachs JD, Sarhan M, Seffrin JR. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet. 2010;376(9747):1186\u201393. https:\/\/doi.org\/10.1016\/S0140-6736(10)61152-X. Epub 2010 Aug 13. PMID: 20709386.","journal-title":"Lancet"},{"key":"310_CR13","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/1472-6963-13-304","volume":"13","author":"E Tekinturhan","year":"2013","unstructured":"Tekinturhan E, Audureau E, Tavolacci MP, et al. Improving access to care in low and middle-income countries: institutional factors related to enrollment and patient outcome in a cancer drug access program. BMC Health Serv Res. 2013;13:304. https:\/\/doi.org\/10.1186\/1472-6963-13-304.","journal-title":"BMC Health Serv Res"},{"issue":"S8","key":"310_CR14","doi-asserted-by":"publisher","first-page":"viii43","DOI":"10.1093\/annonc\/mdl987","volume":"17","author":"S Lassarat","year":"2006","unstructured":"Lassarat S, Jootar S. Ongoing challenges of a global international patient assistance program. Ann Oncol. 2006;17(S8):viii43\u20136.","journal-title":"Ann Oncol"},{"issue":"5","key":"310_CR15","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1177\/1078155219881680","volume":"26","author":"M Crist","year":"2020","unstructured":"Crist M, Emadi A, Duffy A. Real-world experience managing blinatumomab toxicities in adults with relapsed\/refractory acute lymphoblastic leukemia. J Oncol Pharm Pract. 2020;26(5):1080\u20135. https:\/\/doi.org\/10.1177\/1078155219881680.","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"310_CR16","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1188\/16.CJON.466-469","volume":"20","author":"S DePadova","year":"2016","unstructured":"DePadova S, Howlett C, Rivera K. A multidisciplinary approach to standardizing processes for blinatumomab administration. Clin J Oncol Nurs. 2016;20(5):466\u20139. https:\/\/doi.org\/10.1188\/16.CJON.466-469.","journal-title":"Clin J Oncol Nurs"},{"key":"310_CR17","doi-asserted-by":"publisher","first-page":"e28541","DOI":"10.1002\/pbc.28541","volume":"67","author":"K Oranges","year":"2020","unstructured":"Oranges K, Windawi S, Powell S, Dallago D, Escobar N, Rheingold SR. How we infuse blinatumomab. Pediatr Blood Cancer. 2020;67:e28541. https:\/\/doi.org\/10.1002\/pbc.28541. Published online ahead of print, 2020 Jun 23.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"310_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/NAN.0000000000000283","volume":"41","author":"S Szoch","year":"2018","unstructured":"Szoch S, Boord C, Duffy A, Patzke C. Addressing administration challenges associated with blinatumomab infusions: a multidisciplinary approach. J Infus Nurs. 2018;41(4):241\u20136. https:\/\/doi.org\/10.1097\/NAN.0000000000000283.","journal-title":"J Infus Nurs"},{"key":"310_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/1178632921999652","author":"T Ojo","year":"2021","unstructured":"Ojo T, Kabasele L, Boyd B, et al. The role of implementation science in advancing resource generation for health interventions in low- and middle-income countries. Health Serv Insights. 2021. https:\/\/doi.org\/10.1177\/1178632921999652.","journal-title":"Health Serv Insights"},{"key":"310_CR20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1748-5908-4-50","volume":"4","author":"LJ Damschroder","year":"2009","unstructured":"Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implementation Sci. 2009;4:50. https:\/\/doi.org\/10.1186\/1748-5908-4-50.","journal-title":"Implementation Sci"},{"key":"310_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13012-019-0892-4","volume":"14","author":"TJ Waltz","year":"2019","unstructured":"Waltz TJ, Powell BJ, Fern\u00e1ndez ME, et al. Choosing implementation strategies to address contextual barriers: diversity in recommendations and future directions. Implementation Sci. 2019;14:42. https:\/\/doi.org\/10.1186\/s13012-019-0892-4.","journal-title":"Implementation Sci"},{"key":"310_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13012-020-0977-0","volume":"15","author":"AR Means","year":"2020","unstructured":"Means AR, Kemp CG, Gwayi-Chore MC, et al. Evaluating and optimizing the Consolidated Framework for Implementation Research (CFIR) for use in low- and middle-income countries: a systematic review. Implementation Sci. 2020;15:17. https:\/\/doi.org\/10.1186\/s13012-020-0977-0.","journal-title":"Implementation Sci"},{"issue":"3","key":"310_CR23","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10552-018-1008-1","volume":"29","author":"S Ramanadhan","year":"2018","unstructured":"Ramanadhan S, Davis MM, Armstrong R, Baquero B, Ko LK, Leng JC, Salloum RG, Vaughn NA, Brownson RC. Participatory implementation science to increase the impact of evidence-based cancer prevention and control. Cancer Causes Control. 2018;29(3):363\u20139. https:\/\/doi.org\/10.1007\/s10552-018-1008-1. Epub 2018 Feb 7. PMID: 29417296; PMCID: PMC5858707.","journal-title":"Cancer Causes Control"},{"issue":"1","key":"310_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13011-019-0222-5","volume":"14","author":"MG Ehrhart","year":"2019","unstructured":"Ehrhart MG, Torres EM, Hwang J, Sklar M, Aarons GA. Validation of the Implementation Climate Scale (ICS) in substance use disorder treatment organizations. Subst Abuse Treat Prev Policy. 2019;14(1):35. https:\/\/doi.org\/10.1186\/s13011-019-0222-5. PMID: 31443666; PMCID: PMC6708170.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"310_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1748-5908-9-7","volume":"9","author":"CM Shea","year":"2014","unstructured":"Shea CM, Jacobs SR, Esserman DA, et al. Organizational readiness for implementing change: a psychometric assessment of a new measure. Implementation Sci. 2014;9:7. https:\/\/doi.org\/10.1186\/1748-5908-9-7.","journal-title":"Implementation Sci"},{"issue":"1","key":"310_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13012-017-0635-3","volume":"12","author":"BJ Weiner","year":"2017","unstructured":"Weiner BJ, Lewis CC, Stanick C, Powell BJ, Dorsey CN, Clary AS, Boynton MH, Halko H. Psychometric assessment of three newly developed implementation outcome measures. Implement Sci. 2017;12(1):108. https:\/\/doi.org\/10.1186\/s13012-017-0635-3. PMID: 28851459; PMCID: PMC5576104.","journal-title":"Implement Sci"},{"key":"310_CR27","unstructured":"CFIR Interview Development Guide. https:\/\/cfirguide.org\/guide\/app\/#\/."},{"issue":"8","key":"310_CR28","first-page":"514","volume":"42","author":"CL Ventola","year":"2017","unstructured":"Ventola CL. Cancer immunotherapy, part 3: challenges and future trends. P T. 2017;42(8):514\u201321.","journal-title":"P T"},{"issue":"4","key":"310_CR29","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/S1470-2045(20)30022-X","volume":"21","author":"R Atun","year":"2020","unstructured":"Atun R, Bhakta N, Denburg A, Frazier AL, Friedrich P, Gupta S, Lam CG, Ward ZJ, Yeh JM, Allemani C, Coleman MP, Di Carlo V, Loucaides E, Fitchett E, Girardi F, Horton SE, Bray F, Steliarova-Foucher E, Sullivan R, Aitken JF, Banavali S, Binagwaho A, Alcasabas P, Antillon F, Arora RS, Barr RD, Bouffet E, Challinor J, Fuentes-Alabi S, Gross T, Hagander L, Hoffman RI, Herrera C, Kutluk T, Marcus KJ, Moreira C, Pritchard-Jones K, Ramirez O, Renner L, Robison LL, Shalkow J, Sung L, Yeoh A, Rodriguez-Galindo C. Sustainable care for children with cancer: a Lancet Oncology Commission. Lancet Oncol. 2020;21(4):e185\u2013224. https:\/\/doi.org\/10.1016\/S1470-2045(20)30022-X. PMID: 32240612.","journal-title":"Lancet Oncol"},{"issue":"10","key":"310_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13012-015-0209-1","volume":"12","author":"BJ Powell","year":"2015","unstructured":"Powell BJ, Waltz TJ, Chinman MJ, Damschroder LJ, Smith JL, Matthieu MM, Proctor EK, Kirchner JE. A refined compilation of implementation strategies: results from the Expert Recommendations for Implementing Change (ERIC) project. Implement Sci. 2015;12(10):21. https:\/\/doi.org\/10.1186\/s13012-015-0209-1. PMID: 25889199; PMCID: PMC4328074.","journal-title":"Implement Sci"},{"key":"310_CR31","doi-asserted-by":"publisher","unstructured":"Kirchner JE, Smith JL, Powell BJ, Waltz TJ, Proctor EK. Getting a clinical innovation into practice: an introduction to implementation strategies. Psychiatry Res.\u00a02020;283:112467.\u00a0https:\/\/doi.org\/10.1016\/j.psychres.2019.06.042. Epub 2019 Jul 2. PMID: 31488332; PMCID: PMC7239693.","DOI":"10.1016\/j.psychres.2019.06.042"},{"key":"310_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13012-015-0295-0","volume":"10","author":"TJ Waltz","year":"2015","unstructured":"Waltz TJ, Powell BJ, Matthieu MM, et al. Use of concept mapping to characterize relationships among implementation strategies and assess their feasibility and importance: results from the Expert Recommendations for Implementing Change (ERIC) study. Implementation Sci. 2015;10:109. https:\/\/doi.org\/10.1186\/s13012-015-0295-0.","journal-title":"Implementation Sci"},{"key":"310_CR33","unstructured":"Common terminology criteria for adverse events (CTCAE). Published November 27, 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"issue":"9","key":"310_CR34","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2105\/ajph.89.9.1322","volume":"89","author":"RE Glasgow","year":"1999","unstructured":"Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89(9):1322\u20137. https:\/\/doi.org\/10.2105\/ajph.89.9.1322. PMID: 10474547; PMCID: PMC1508772.","journal-title":"Am J Public Health"},{"issue":"9","key":"310_CR35","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1080\/13696998.2017.1344127","volume":"20","author":"TE Delea","year":"2017","unstructured":"Delea TE, Amdahl J, Boyko D, Hagiwara M, Zimmerman ZF, Franklin JL, Cong Z, Hechmati G, Stein A. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective. J Med Econ. 2017;20(9):911\u201322. https:\/\/doi.org\/10.1080\/13696998.2017.1344127. Epub 2017 Jul 11. PMID: 28631497.","journal-title":"J Med Econ"},{"issue":"5","key":"310_CR36","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1517\/14740338.2013.795944","volume":"12","author":"G Alatrash","year":"2013","unstructured":"Alatrash G, Jakher H, Stafford PD, Mittendorf EA. Cancer immunotherapies, their safety and toxicity. Expert Opin Drug Saf. 2013;12(5):631\u201345. https:\/\/doi.org\/10.1517\/14740338.2013.795944. Epub 2013 May 14. PMID: 23668362.","journal-title":"Expert Opin Drug Saf"},{"key":"310_CR37","volume-title":"Increasing access, advancing quality, saving lives","author":"CureAll framework: WHO Global Initiative for Childhood Cancer","year":"2021","unstructured":"CureAll framework: WHO Global Initiative for Childhood Cancer. Increasing access, advancing quality, saving lives. Geneva: World Health Organization; 2021."},{"key":"310_CR38","unstructured":"World Health Organization and St. Jude Children\u2019s Research Hospital to dramatically increase global access to childhood cancer medicines - St. Jude Children\u2019s Research Hospital. (2021, December 13). Retrieved January 3, 2022, from https:\/\/www.stjude.org\/media-resources\/news-releases\/2021-medicine-science-news\/who-stjude-to-dramatically-increase-global-access-to-childhood-cancer-medicines.html."}],"container-title":["Implementation Science Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43058-022-00310-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43058-022-00310-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43058-022-00310-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T04:13:37Z","timestamp":1654920817000},"score":1,"resource":{"primary":{"URL":"https:\/\/implementationsciencecomms.biomedcentral.com\/articles\/10.1186\/s43058-022-00310-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,11]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["310"],"URL":"https:\/\/doi.org\/10.1186\/s43058-022-00310-5","relation":{},"ISSN":["2662-2211"],"issn-type":[{"value":"2662-2211","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,11]]},"assertion":[{"value":"26 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study procedures were approved by the St. Jude Children\u2019s Research Hospital Institutional Review Board (21\u20130902).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Duffy reports receiving an unrestricted Amgen Foundation Grant as part of the submitted work. Dr. Duffy, Dr. Santana, Dr. Inaba, and Dr. Jeha serve on a scientific advisory committee for the Blincyto Humanitarian Access Program.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}